BioPharma Dive3h
FDA approves first-of-its-kind RNA drug for hemophilia
The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...
BioPharma Dive3h
FDA broadens use of Novartis’ radiopharma drug Pluvicto
Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...
Johnson & Johnson unit ordered to pay $1.64 billion in HIV drug marketing case
A federal judge ordered a Johnson & Johnson unit on Friday to pay the U.S. government $1.64 billion after a jury found it ...
Fierce Pharma6h
Sanofi's versatile Qfitlia scores FDA nod to enter crowded hemophilia market
Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...
The American Journal of Managed Care6h
FDA Approves Fitusiran for Reducing Bleeds in Patients With Hemophilia A/B
Data from the ATLAS research comprises a series of trials that have yielded years of long-term, comprehensive data on safety ...
Fierce Biotech6h
'It's just ugly': Federal funding cuts to Columbia University leave chronic fatigue research in limbo
Ian Lipkin, M.D., and his team at Columbia University submitted a paper for publication that suggests certain approved drugs could possibly be repurposed for a severe fatigue condition that currently ...
Fierce Pharma6h
Novartis' prostate cancer drug Pluvicto wins key FDA nod toward $5B-plus sales target
After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...
Lexicon Pharmaceuticals, Novo Nordisk strike obesity-drug license deal worth up to $1B
Lexicon Pharmaceuticals Inc. (Nasdaq: LXRX) said March 28 it will exclusively license its drug candidate LX9581 to Danish ...
Sanofi’s Easier to Use Hemophilia Drug Approved by US FDA
Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US ...
Durham biotech defends lead product after concerns surface
A Durham company is pushing back on media reports questioning the safety of its lead product as the firm begins its commercial launch.
US FDA approves Sanofi's bleeding disorder therapy
The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, paving the way for a new type of ...
WISH-TV9h
European regulators reject Lilly’s US-approved Alzheimer’s treatment
European regulatory committee rejects Lilly's Alzheimer's disease treatment due to potential risks of brain bleeding and ...